| Literature DB >> 23786966 |
Fabrice Michel1, Karine Baumstarck, Agathe Gosselin, Pierre Le Coz, Thierry Merrot, Sophie Hassid, Kathia Chaumoître, Julie Berbis, Claude Martin, Pascal Auquier.
Abstract
BACKGROUND: The development of new therapeutics has led to progress in the early management of congenital diaphragmatic hernia (CDH) in pediatric intensive care units (PICU). Little is known about the impact on the quality of life (QoL) of children and their family. The aim of this study was to assess the impact of CDH treated according to the most recent concepts and methods outlined above on child survivors' QoL and their parents' QoL. PATIENTS AND METHODS: This study incorporated a cross-sectional design performed in two PICU (Marseille, France). Families of CDH survivors born between 1999 and 2008 were eligible. The following data were recorded: socio-demographics, antenatal history and delivery, initial hospitalization history. Self-reported data were collected by mail, including current clinical problems of the children (13-symptom list), children's QoL (Kidscreen-27 questionnaire), and parents' QoL (Short-Form 36 questionnaire). Children's QoL score was compared with controls and QoL of survivors of childhood leukemia. Parent's QoL was compared with controls. Non-parametric statistics were employed.Entities:
Mesh:
Year: 2013 PMID: 23786966 PMCID: PMC3718687 DOI: 10.1186/1750-1172-8-89
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Patients characteristics
| Gender | Girls n (%) | 11 (34.4) |
| | Boys n (%) | 21 (65.6) |
| Age (yrs) | M±SD | 6.7 ± 3.3 |
| | m (min/max) | 5.8 (2.6/13.8) |
| Current BMI z-score | M±SD | −1.4 ± 1.5 |
| | m (min/max) | −2,1(−4,0/2,2) |
| CDH side | Left n (%) | 27 (84.4) |
| | Right n (%) | 5 (15.6) |
| | ||
| Prenatal diagnosis | Yes n (%) | 19 (59.4) |
| Birth weight (g) | M±SD | 2996 ± 709 |
| | m (min/max) | 3100 (900/4000) |
| Term (WOG) | M±SD | 38.2 ± 2.9 |
| | m (min/max) | 39 (27/41) |
| Birth weight z-score | M±SD | −0.5 ± 0.7 |
| | m (min/max) | 0.6(−2.2/1.2) |
| Caesarean | Yes n (%) | 10 (31.3) |
| Surfactant | Yes n (%) | 13 (40.6) |
| MV Duration (d) | M±SD | 13.0 ± 12.2 |
| | m (min/max) | 10(1/57) |
| HFO | Yes n (%) | 24 (75.0) |
| Duration (d) | M±SD | 13.1 ± 13.2 |
| | m (min/max) | 9 (1/57) |
| Amines | Yes n (%) | 23 (71.9) |
| Duration (d) | M±SD | 7.4 ± 5.2 |
| | m (min/max) | 6 (1–26) |
| NO | Yes n (%) | 19 (59.4) |
| Duration (d) | M±SD | 6.9 ± 7.0 |
| | m (min/max) | 4 (1–25) |
| Sedation (d) | M±SD | 10.7 ± 12.5 |
| | m (min-max) | 6 (1/57) |
| ICU LOS (d) | M±SD | 18.6 ± 18.3 |
| | m (min/max) | 14 (3/92) |
| CDH repair (day of life) | M±SD | 2.7 ± 2.3 |
| | m (min/max) | 1(1/12) |
| Surgery | Simple | 27 (84.4) |
| | Others | 5 (15.6) |
| Hospital LOS (d) | M±SD | 40.2 ± 34.0 |
| | m (min/max) | 28(10/140) |
| Weight at discharge (g) | M±SD | 3569 ± 829 |
| | m (min/max) | 3380 (1545/4855) |
| GER at discharge | Yes n(%) | 14 (43.8) |
WOG week of gestation, LOS length of stay, BMI Body mass index, MV, mechanical Ventilation, HFO High frequency oscillation, NO nitric oxide, GER Gastro-esophageal reflux.
M±SD mean±standard deviation, m (min/max), median (minimum/maximum).
Current clinical problems of CHD survivors at the time of response
| Digestive symptoms (total) | 11 (34.4) |
| Vomiting | 3 (9.3) |
| Gastro-oesophageal reflux | 2 (6.3) |
| Constipation | 3 (9.3) |
| Diarrhea | 1 (3.1) |
| Abdominal pain | 3 (9.3) |
| Medical treatment | 3 (9.3) |
| Respiratory symptoms (total) | 7 (21.9) |
| Dyspnea at rest | 2 (6.3) |
| Exertional dyspnea | 3 (9.3) |
| Nocturn dyspnea | 1 (3.2) |
| Pain chest | 0 (0) |
| Respiratory treatment | 2 (6.3) |
| Repeated respiratory tract infection | 4 (12.5) |
| Hospitalisation for respiratory trouble | 3 (9.3) |
| Neuropsychologic symptoms (total) | 8 (26.7) |
| Cerebral palsy | 1 (3.1) |
| Mental retardation | 1 (3.1) |
| Neurological following | 1 (3.1) |
| Psychological following | 7 (21.8) |
| Orthopedic symptoms (total) | 4 (12.5) |
| Difficult walking | 2 (6.3) |
| Kinesitherapy | 2 (6.3) |
| Orthopedic treatment | 1 (3.2) |
| Total | 21 (65.6) |
Self-reported data from the CDH survivors and their parents
| Physical well-being | 53.4 ± 10.7 | 5,9 (1,7 ; 10,1) | −11,6 (−15,6 ; -7,63) |
| Psychological well-being | 53.4 ± 9.5 | 2,3 (−1,5 ; 6,3) | −23,8 (−27,2 ; -20,3) |
| Parents and autonomy | 47.3 ± 7.9 | −0, (−5,4 ; 3,5) | −14,3 (−17,4 ; -11,1) |
| Peers and social support | 44.5 ± 9.5 | 0,1 (−5,0 ; 5,3) | −16,3 (−19,8 ; -12,8) |
| School | 53.5 ± 10.0 | 3,0 (−1,2 ; 7,3) | −13,2 (−17,0 ; -9,44) |
| | | ||
| Emotional symptoms | 3.0 ± 2.7 | - | - |
| Conduct problems | 2.5 ± 1.7 | - | - |
| Hyperactivity | 4.1 ± 2.4 | - | - |
| Peer problems | 1.6 ± 2.4 | - | - |
| Prosocial | 8.2 ± 1.5 | - | - |
| Total difficulties | 11.3 ± 5.7 | - | - |
| | | | |
| | | ||
| Physical function | 92.5 ± 13.2 | - | - |
| Social functioning | 86.7 ± 19.1 | - | - |
| Role physical | 89.9 ± 15.3 | - | - |
| Role emotional | 63.2 ± 9.1 | - | - |
| Mental health | 71.4 ± 14.2 | - | - |
| Vitality | 71.7 ± 17.0 | - | - |
| Body pain | 83.8 ± 22.5 | - | - |
| General health | 79.7 ± 17.3 | - | - |
| Physical composite score | 55.9 ± 6.1 | - | - |
| Mental composite score | 46.7 ± 5.6 | - | - |
M±SD mean±standard deviation.
* Higher score, higher QoL level.
LEA long term leucemia survivors, norms, Kidscreen norms (sex- and gender- matched).
+ Diff (95% CI) CHD score – LEA score (95% confidence interval of difference); ++ Diff (95% CI), CHD score – norm score (95% confidence interval of difference).
Figure 1Comparaison of Kidscreen 27 scores of CDH survivors with long term leucemia survivors (LEA), and norms. * p < 0.001 between sample and Kidscreen norms (sex- and gender- matched). † p < 0.01 between sample and Kidscreen scores of LEA cohort.
Children’ quality of life (Kidscreen-27): association with socio-demographic parameters and initial management
| 50.0 ± 9.2 | 49.0 ± 6.6 | 45.0 ± 8.9 | 44.2 ± 10.6 | 51.0 ± 9.0 | ||
| | 58.8 ± 11.0 | 60.3 ± 9.6 | 50.5 ± 5.3 | 45.1 ± 7.8 | 57.3 ± 10.6 | |
| | 0.056 | 0.613 | 0.114 | |||
| 49.9 ± 10.3 | 48.9 ± 7.5 | 43.7 ± 8.1 | 40.5 ± 10.0 | 50.7 ± 8.4 | ||
| | 56.2 ± 10.4 | 57.0 ± 9.7 | 50.7 ± 6.2 | 48.0 ± 7.9 | 55.8 ± 10.8 | |
| | 0.095 | 0.213 | ||||
| −0.057 | −0.020 | 0.099 | 0.358 | 0.047 | ||
| | 0.762 | 0.914 | 0.639 | 0.062 | 0.807 | |
| −0.249 | −0.397 | −0.062 | 0.374 | −0.281 | ||
| | 0.184 | 0.772 | 0.055 | 0.140 | ||
| 48.3 ± 12.5 | 53.6 ± 10.5 | 42.2 ± 7.7 | 38.2 ± 7.5 | 56.6 ± 12.3 | ||
| | 54.85 ± 9.9 | 53.28 ± 9.5 | 49.02 ± 7.4 | 46.66 ± 9.3 | 52.78 ± 9.5 | |
| | 0.068 | 0.924 | 0.074 | 0.334 | ||
| 51.9 ± 9.3 | 51.2 ± 7.2 | 48.5 ± 7.9 | 45.9 ± 12.1 | 51.9 ± 5.9 | ||
| | 54.2 ± 11.5 | 54.5 ± 10.6 | 46.8 ± 8.09 | 43.7 ± 7.69 | 54.4 ± 11.6 | |
| | 0.572 | 0.504 | 0.600 | 0.832 | 0.506 | |
| 47.3 ± 8.9 | 51.5 ± 9.1 | 41.3 ± 6.6 | 39.8 ± 8.0 | 48.4 ± 9.2 | ||
| | 54.9 ± 10.3 | 54.2 ± 10.3 | 48.3 ± 6.8 | 44.9 ± 8.8 | 55.5 ± 10.3 | |
| 0.051 | 0.657 | 0.200 | 0.101 |
* mean±standard deviation, p p-value Mann–Whitney test.
** Spearman’s correlation coefficient p, p-value Spearman’s test.
PhWB, Physical well-being PsWB, Psychological well-being Par&Au, Parents and autonomy PSS, Peers and social support Sch, School.
higher score represents higher level of QoL.
Bold values, p < 0.05.
Figure 2Comparisons of SF36 dimensions scores between the parents of CDH survivors and norms. * p < 0.05 between sample and SF-36 norms (sex- and gender- matched).
Parents’ quality of life (SF36): associations with socio-demographic parameters and initial management
| 91.5 ± 15.7 | 82.6 ± 22.3 | 87.5 ± 16.2 | 61.6 ± 10.4 | 68.5 ± 13.9 | 67.4 ± 16.3 | 80.4 ± 23.8 | 75.0 ± 18.9 | 55.0 ± 6.7 | 45.1 ± 5.7 | ||
| | 93.8 ± 9.2 | 92.3 ± 12.0 | 93.3 ± 13.8 | 65.4 ± 6.7 | 75.8 ± 14.1 | 78.1 ± 16.5 | 88.5 ± 20.6 | 86.8 ± 12.1 | 57.3 ± 5.1 | 49.0 ± 4.9 | |
| | 0.683 | 0.301 | 0.185 | 0.508 | 0.134 | 0.072 | 0.245 | 0.085 | 0.290 | ||
| 92.8 ± 14.1 | 87.8 ± 19.2 | 91.8 ± 14.0 | 62.2 ± 8.6 | 71.1 ± 14.9 | 72.0 ± 18.0 | 87.1 ± 21.8 | 80.8 ± 16.0 | 56.9 ± 5.6 | 46.3 ± 5.9 | ||
| | 91.0 ± 8.2 | 85.0 ± 20.5 | 80.0 ± 19.5 | 68.3 ± 10.9 | 73.0 ± 11.0 | 70.0 ± 12.0 | 66.4 ± 19.6 | 74.0 ± 24.1 | 51.1 ± 7.0 | 48.7 ± 4.3 | |
| | 0.238 | 0.637 | 0.091 | 0.329 | 0.955 | 0.933 | 0.655 | 0.254 | |||
| 93,7 ± 3,2 | 83,0 ± 6,2 | 87,0 ± 3,7 | 60,7 ± 2,8 | 69,8 ± 3,6 | 66,9 ± 3,4 | 84,1 ± 6,7 | 70,8 ± 5,0 | 55,2 ± 1,6 | 45,0 ± 1,4 | ||
| | 91,5 ± 3,5 | 89,7 ± 3,6 | 92,3 ± 4,0 | 65,2 ± 1,8 | 72,8 ± 3,8 | 75,78 ± 4,9 | 83,5 ± 5,1 | 87,4 ± 3,0 | 56,5 ± 1,6 | 48,1 ± 1,4 | |
| | 0,848 | 0,711 | 0,304 | 0,487 | 0,159 | 0,794 | 0,339 | ||||
| −0.378 | −0.174 | 0.212 | −0.262 | −0.204 | −0.132 | −0.142 | −0.110 | −0.147 | −0.154 | ||
| | 0.348 | 0.252 | 0.155 | 0.281 | 0.488 | 0.446 | 0.564 | 0.437 | 0.417 | ||
| −0.019 | −0.201 | −0.417 | −0.111 | −0.023 | −0.189 | −0.291 | −0.289 | −0.350 | −0.042 | ||
| | 0.919 | 0.286 | 0.558 | 0.904 | 0.325 | 0.118 | 0.128 | 0.063 | 0.829 | ||
| 87,0 ± 19,0 | 71,4 ± 25,7 | 87,5 ± 19,1 | 63,1 ± 6,6 | 72,9 ± 15,2 | 64,3 ± 13,8 | 68,1 ± 32,2 | 63,9 ± 24,8 | 50,8 ± 8,6 | 45,9 ± 5,0 | ||
| | 94,1 ± 11,0 | 91,1 ± 14,5 | 90,6 ± 14,4 | 63,2 ± 9,8 | 71,0 ± 14,2 | 73,9 ± 17,4 | 88,3 ± 17,2 | 84,5 ± 11,2 | 57,5 ± 4,3 | 46,9 ± 5,9 | |
| | 0,068 | 0,980 | 0,958 | 0,637 | 0,399 | 0,147 | 0,059 | 0,391 | |||
| 90,4 ± 14,3 | 83,8 ± 22,0 | 90,0 ± 15,3 | 65,0 ± 9,5 | 65,8 ± 17,1 | 70,6 ± 15,6 | 78,7 ± 27,0 | 76,1 ± 15,8 | 55,1 ± 5,8 | 45,4 ± 6,7 | ||
| | 93,5 ± 12,8 | 88,1 ± 17,8 | 89,9 ± 15,6 | 62,3 ± 8,98 | 74,3 ± 11,9 | 72,2 ± 17,9 | 86,2 ± 20,3 | 81,5 ± 18,1 | 56,3 ± 6,35 | 47,3 ± 5,13 | |
| | 0,248 | 0,642 | 0,787 | 0,727 | 0,174 | 0,824 | 0,342 | 0,320 | 0,356 | 0,509 | |
| 96,3 ± 5,2 | 90,6 ± 18,6 | 90,6 ± 10,0 | 62,5 ± 14,1 | 70,3 ± 11,1 | 68,8 ± 14,2 | 88,6 ± 20,6 | 70,5 ± 18,7 | 56,2 ± 6,0 | 46,0 ± 5,7 | ||
| | 92,7 ± 13,3 | 86,3 ± 19,7 | 91,1 ± 15,1 | 63,9 ± 6,6 | 72,5 ± 15,3 | 74,1 ± 18,2 | 80,4 ± 23,8 | 83,5 ± 16,6 | 56,0 ± 6,5 | 47,3 ± 5,7 | |
| 0,751 | 0,396 | 0,348 | 0,914 | 0,367 | 0,400 | 0,384 | 0,055 | 0,959 | 0,476 |
* mean±standard deviation p, p-value Mann–Whitney test.
** Spearman’s correlation coefficient p, p-value Spearman’s test.
PF physical functioning, SF social functioning, RP role physical, RE role-emotional, MH mental health, VI vitality, BP bodily pain, GH general health, PCS physical composite score MCS, mental composite score, higher score represents higher level of QoL, Bold values, p < 0.0.